Shielded targeting agents, methods, and in vivo diagnostic system
View Patent ↗A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided.
1. A shielded nanoparticle conjugate comprising:
a nanoparticle;
at least one targeting entity for binding to tumor cells or tissue in vivo, the at least one targeting entity bound to the nanoparticle; and
at least one shielding entity for shielding the at least one targeting entity and for unshielding from the at least one targeting entity in a microenvironment of the tumor cells or tissue in vivo, the at least one shielding entity is selected from a protease sensitive bivalent peptide or a bivalent anti-idiotypic aptamer.
2. The shielded nanoparticle conjugate of claim 1 , wherein the nanoparticle comprises a polymer material.
3. The shielded nanoparticle conjugate of claim 1 , wherein the nanoparticle comprises a non-polymeric material.
4. The shielded nanoparticle conjugate of claim 1 , wherein the nanoparticle comprises a magnetic or paramagnetic material.
5. The shielded nanoparticle conjugate of claim 1 , wherein the at least one targeting entity comprises an antibody, peptide, protein, nucleic acid, small molecule, carbohydrate, or lipid.
6. The shielded nanoparticle conjugate of claim 1 , wherein the bivalent anti-idiotypic aptamer is directed to a tumor metabolite.
7. The shielded nanoparticle conjugate of claim 1 , wherein the at least one targeting entity is an antibody and the at least one shielding entity is a protease-sensitive bivalent peptide that binds to the antigen binding site of the antibody.
8. The shielded nanoparticle conjugate of claim 1 , wherein the at least one targeting entity is an antibody and the at least one shielding entity is a bivalent anti-idiotypic aptamer with a tumor metabolite-binding domain, wherein the bivalent anti-idiotypic aptamer binds to the antigen binding site of the antibody.
9. The shielded nanoparticle conjugate of claim 1 , further comprising at least one detection label.
10. The shielded nanoparticle conjugate of claim 1 , further comprising at least one agent to be delivered to the tumor cells.
11. The shielded nanoparticle conjugate of claim 10 , wherein the at least one agent comprises at least one anti-tumor agent.
12. The shielded nanoparticle conjugate of claim 10 , wherein the at least one agent comprises a contrast imaging agent.
13. The shielded nanoparticle conjugate of claim 1 , wherein said shielded nanoparticle conjugate comprises at least one moiety that exhibits fluorescence, luminescence, magnetic or paramagnetic properties.
14. A method for in vivo imaging in a mammal of tumor cells or tissue that express a selected marker; said method comprising the steps of:
(a) administering to the mammal a composition as recited in claim 1 , wherein the at least one targeting entity targets a selected marker of tumor cells or tissue;
(b) allowing the at least one targeting entity to bind to the selected marker of the tumor cells or tissue in vivo to form a conjugate; and
(c) imaging the tumor cells or tissue with a non-invasive imaging technique that has a resolution enhanced by a presence of the conjugate on or within the tumor cells or tissue in vivo.
15. The method of claim 14 , wherein the non-invasive imaging technique is selected from the group consisting of magnetic resonance imaging (MRI), magnetic spectroscopy, X-ray, positron emission tomography (PET), computer tomography (CT), ultrasonic imaging, and optical imaging.
16. A shielded nanoparticle conjugate comprising:
a nanoparticle;
at least one targeting entity for binding to tumor cells or tissue in vivo, the at least one targeting entity bound to the nanoparticle; and
at least one shielding entity for shielding the at least one targeting entity and for unshielding from the at least one targeting entity in a microenvironment of the tumor cells or tissue in vivo, the at least one shielding entity comprising a pH-sensitive polymer.
17. The shielded nanoparticle conjugate of claim 16 , wherein the nanoparticle comprises a polymer material.
18. The shielded nanoparticle conjugate of claim 16 , wherein the nanoparticle comprises a non-polymeric material.
19. The shielded nanoparticle conjugate of claim 16 , wherein the nanoparticle comprises a magnetic or paramagnetic material.
20. The shielded nanoparticle conjugate of claim 16 , wherein the at least one targeting entity comprises an antibody, peptide, protein, nucleic acid, small molecule, carbohydrate, or lipid.
21. The shielded nanoparticle conjugate of claim 16 , wherein the at least one targeting entity is an antibody and the at least one shielding entity is a pH-sensitive polymer that degrades in an acidic tumor microenvironment.
22. The shielded nanoparticle conjugate of claim 16 , further comprising at least one detection label.
23. The shielded nanoparticle conjugate of claim 16 , further comprising at least one agent to be delivered to the tumor cells.
24. The shielded nanoparticle conjugate of claim 23 , wherein the at least one agent comprises at least one anti-tumor agent.
25. The shielded nanoparticle conjugate of claim 23 , wherein the at least one agent comprises a contrast imaging agent.
26. The shielded nanoparticle conjugate of claim 16 , wherein said shielded nanoparticle conjugate comprises at least one moiety that exhibits fluorescence, luminescence, magnetic or paramagnetic properties.
27. A method for in vivo imaging in a mammal of tumor cells or tissue that express a selected marker; said method comprising the steps of:
(a) administering to the mammal a composition as recited in claim 16 , wherein the at least one targeting entity targets a selected marker of tumor cells or tissue;
(b) allowing the at least one targeting entity to bind to the selected marker of the tumor cells or tissue to form a conjugate; and
(c) imaging the tumor cells or tissue with a non-invasive imaging technique that has a resolution enhanced by the conjugate present on or within the tumor cells or tissue.
28. The method of claim 27 , wherein the non-invasive imaging technique is selected from the group consisting of magnetic resonance imaging (MRI), magnetic spectroscopy, X-ray, positron emission tomography (PET), computer tomography (CT), ultrasonic imaging, and optical imaging.